All In Biotech

Drug Trial Radar · NCT07057427

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 812 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

812

Planned (sponsor's estimate)

Start

Jun 24, 2025

Primary completion

Jun 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Nab paclitaxelDrug

    Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)

  • Docetaxel and CarboplatinDrug

    Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1)

  • Trastuzumab + PertuzumabDrug

    Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR)Time frame: through study completion, up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan cancer hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.